Hereditary cancer

Gabriel Capella Munar/ Conxi Lázaro Garcia

PRINCIPAL INVESTIGATORS
  • Joan Brunet Vidal
  • Marta Pineda Riu
  • Laura Valle Velasco
  • Barbara Rivera Polo
CLINICAL RESEARCHERS
  • Alexandre Teule Vega
POSTDOCTORAL RESEARCHERS
  • Jesus Del Valle Dominguez
  • Paula Rofes Terrón
  • Xavier Muñoz Miralles
  • Nuria Dueñas Cid
  • Fátima Marín Nieto
  • Mireia Morell Ginesta
  • Maria Lídia Feliubadaló Elorza
  • Juana Fernandez Rodriguez
  • Nuria Catasus Segura
  • Edgar Creus Bachiller
  • Paula Climent Canto
  • Sara Crespo Yanguas
  • Mariona Terradas Ill
  • Jacopo Boni
  • Ana Filipa Brinco De Oliveira Ponte
PREDOCTORAL RESEARCHERS
  • Carla Roca Grau
  • Clara Nogue Anson
  • Oscar Mesia Carbonell
  • Sara Ortega Bertran
  • Elisabet Munte Roca
  • Julen Viana Errasti
  • Manuel Torralba Carnerero
  • Anne Sophie Axelle Chong
SCIENTIFIC SUPPORT
  • Marina Galan Rueda
  • Gemma Guillamon Vidal
  • Carolina Gomez Hernandez
  • Raquel Cuesta Llorente
  • Julia Canet Hermida
  • Gemma Aiza Buscarons
  • Olga Campos Mata
  • Lluis Salvador Hernandez
  • Mireia Ramos Muntada
  • Guillem Campo Fernandez
  • Eva Montes Segura
  • Miriam Fernandez Gonzalez
  • Cristina Rioja Llerena
MANAGEMENT SUPPORT
  • Guillem Torcal García
  • Patricia Prada Dacasa
  • Iolanda Rubio Carre
STUDENTS
  • Llara Perez Chicharro
Cancer
Oncobell

Scientific production

36

PAPERS

Average IF: 5,25

11

LED PAPERS

Average IF: 7,66

10 PUBLICATIONS IN FIRST DECILE

22 PUBLICATIONS IN FIRST QUARTILE

33 PUBLICATIONS IN OPEN ACCESS

Selected publications

  • Ortega Bertran,S;Fernández Rodríguez,J;Magallón Lorenz,M;Zhang,X;Creus Bachiller,E;Diazgranados,AP;Uriarte Arrazola,I et al, Triple Combination of MEK, BET, and CDK Inhibitors Significantly Reduces Human Malignant Peripheral Nerve Sheath Tumors in Mouse Models., Clin. Cancer Res., 2024;31(5):907-920, doi:10.1158/1078-0432.CCR-24-2807
  • Marín,F;Canet Hermida,J;Bianchi,V;Chung,JL;Wimmer,K;Foulkes,W;Pérez Alonso,V et al, A Validated Highly Sensitive Microsatellite Instability Assay Accurately Identifies Individuals Harboring Biallelic Germline PMS2 Pathogenic Variants in Constitutional Mismatch Repair Deficiency, Clin Chem, 2024;70(5):737-746, doi:10.1093/clinchem/hvae027
  • Gonzalez Abuin,N;Pons,T;Fuster,T;Quintana,I;Terradas,M;Aiza,G;Brunet,J et al, Lack of evidence for germline WWP1 pathogenic variants in gastrointestinal polyposis and other phenotypes suggestive of PTEN-hamartoma-tumor syndrome, Genes Dis., 2024;11(2):524-527, doi:10.1016/j.gendis.2023.03.011
  • Munté,E;Roca,C;Del Valle,J;Feliubadaló,L;Pineda,M;Gel,B;Castellanos,E et al, Detection of germline CNVs from gene panel data: benchmarking the state of the art, Brief. Bioinform., 2024;26(1):doi:10.1093/bib/bbae645
  • Moreno Cabrera,JM;Feliubadaló,L;Pineda,M;Prada Dacasa,P;Ramos Muntada,M;Del Valle,J;Brunet,J et al, SpadaHC: a database to improve the classification of variants in hereditary cancer genes in the Spanish population, Database, 2024;2024doi:10.1093/database/baae055

Research highlights

PROJECTS

5 Granted competitive projects
37 Ongoing competitive projects

10 Ongoing clinical trials
6 Ongoing non-competitive projects

PUBLISHED WORKS

3 Clinical guidelines
1 thesis

NETWORKS

ERN GENTURIS
SOLVE-RD
EHTG
ClinGen
CIMBA
COMPLEXO
ENIGMA
C4CMMRD
IRRDC
NRTO
IMPACT GENO
INGENIO
SPADA
CRECE
CIBERONC
DIRECt
AGAUR SGR GRC-2021
AGAUR SGR GRE-2021
GETTHI
IMPaCT VUSCan
IMPaCT Genómica

Selected projects

  • PID2023-151585OB-I00. Cáncer endometrial y pancreático en síndrome de Lynch: retos más allá del riesgo de cáncer colorectal. Ministerio de Ciencia e Innovación. Budget: 387.500€. 2025-2028. PI: Pineda Riu, Marta/Capellá Munar, Gabriel.
  • PID2020-112595RB-I00/PID2023-151585OB-I00. Polymerase proofREADing-deficient tumors: genetics and immune biology insights for improved predictive MEDicine. Ministerio de Ciencia e Innovación. Budget: 780.750€. 2022-2026. PI: VALLE VELASCO, LAURA.
  • LABAE235269RIVE. DELINEATING THE INVOLVEMENT OF miRNA BIOGENESIS GENES IN TUMOR DEVELOPMENT (miRNAtude). Asociación Española Contra el Cáncer (AECC). Budget: 300.000€. 2023-2026. PI: RIVERA POLO, BARBARA.
  • PI23/00017. Evaluación de la VIabilidad y coste-efectividad de un cribado de Variantes constitucionales EN una cohorte prospectiva de pacientes con CÁNcer (VIVEN-CAN). Instituto de Salud Carlos III (ISCIII). Budget: 227.500€. 2024-2026. PI: LAZARO GARCIA, CONCEPCION.
  • MAR24002. Personalized prevention of endometrial cancer in Lynch syndrome: empowering women in the decision of risk reducing surgery.. Fundació La Marató de TV3. Budget: 149.998,83€. 2025-2028. PI: Capellá Munar, Gabriel.